

# WFS1 R818H — Wolframin

Arg→His p818 luminal AM=0.11 ddg=-0.17 pLDDT=86. ClinVar Conflicting evidence. Atlas mechanism: see structural analysis.

## IDENTITY

Variant	R818H (p.Arginine818Histidine)
DNA change	c.2453G>A
Gene · Protein	WFS1 · Wolframin (890 aa)
UniProt	O76024 · WFS1_HUMAN
ClinVar accession	VCV000215414
Amino acid change	partial charge reduction

## STRUCTURAL CONTEXT

AlphaFold model	AF-O76024-F1, v6
pLDDT at residue 818	<b>85.81</b> HIGH CONFIDENCE
Domain	C-terminal luminal domain (653-869)
Position context	C-terminal luminal domain
IDR flag	No — pLDDT well above 50 threshold

Position analysis: GLN819 (2.4 Å), LEU817 (2.5 Å), SER821 (4.4 Å). Same Q819 long-range contact as R818C, K705N. Multi-variant convergence. The Atlas's neighbor extraction surfaces this variant's contacts.

## COMPUTATIONAL PREDICTIONS

ALPHAMISSENSE

**0.109**am\_class: **LBen** —  
threshold > 0.564DYNAMUT2  $\Delta\Delta G$ **-0.17** kcal/

mol

Destabilising · Job  
177992512014

PLDDT (ALPHAFOLD)

**85.81**

high confidence

## CLINICAL EVIDENCE

ClinVar classification

### CONFLICTING CLASSIFICATIONS OF PATHOGENICITY

Review status

criteria provided, conflicting classifications

Last evaluated

2025/12/18 00:00

Inheritance

Conflicting ClinVar classifications.

WFS1 variant landscape

R818H is 1 of ~326 pathogenic-spectrum variants in WFS1 (out of 2,243 in ClinVar)

- (no specific conditions catalogued)

## RESEARCH PATH DECISION TREE

$\Delta\Delta G < 2$  + binding site affected → CATEGORY 3 – docking experiments  $\Delta\Delta G$  2–4 → CATEGORY 2 – pharmacological chaperones  $\Delta\Delta G > 4$  → CATEGORY 1 – gene therapy pLDDT < 50 → CATEGORY 5 – IDR, experimental only Stable fold + functional site hit → CATEGORY 4 – site-specific docking

**Cat 3/4 — see structural prose.** AlphaMissense below threshold (AM under-call class) but mechanism is structurally clear from neighbor analysis. Therapeutic strategy: site-directed at the contacts identified above.

Same Q819 hub as R818C, K705 region.